ONCOLOGY® Companion, Volume 36, Supplement 11

home / journals / oncology-companion / oncology-companion-volume-36-supplement-12
Recap: Discussing Treatment Updates in CRC With a Patient Advocate

Recap: Discussing Treatment Updates in CRC With a Patient Advocate

December 26th 2022
Article

Elle Charnisky, a patient with stage IV HER2+ metastatic colorectal cancer (mCRC), joins a panel of healthcare professionals to discuss how HER2 alternations are detected and how patients with HER2+ mCRC are optimally treated to improve outcomes.

Recap: Use of Tazemetostat in EZH2-Mutant vs Wild-Type Follicular Lymphoma

Recap: Use of Tazemetostat in EZH2-Mutant vs Wild-Type Follicular Lymphoma

December 23rd 2022
Article

Expert hematologist-oncologists discuess the E7438-G000-101 clinical trial and consider the EZH2 inhibitor tazemetostat as a treatment for relapsed/refractory follicular lymphoma.

Recap: MSKCC and DFCI Debate Current Treatment Strategies in Multiple Myeloma

Recap: MSKCC and DFCI Debate Current Treatment Strategies in Multiple Myeloma

December 22nd 2022
Article

Experts from leading institutions debate the latest advances in multiple myeloma.

Recap: Selinexor, Carfilzomib, and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Recap: Selinexor, Carfilzomib, and Dexamethasone for Relapsed/Refractory Multiple Myeloma

December 20th 2022
Article

Joseph Mikhael, MD, and Hakan Kaya, MD, review key efficacy and safety data for the combination of selinexor, carfilzomib, and dexamethasone in R/R MM and discuss optimal dosing and adverse event management strategies for selinexor.